Voluntary alcohol consumption and plasma beta-endorphin levels in alcohol preferring rats chronically treated with levetiracetam: A preliminary study

Physiology and Behavior

Volumn 102, Issue 5, 2011, Pages 538-541

  Zalewska Kaszubska, Jadwiga ^a   Bajer, Bartosz ^a   Czarnecka, Elzbieta ^a   Dyr, Wanda ^b   Gorska, Dorota ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

Author keywords

Alcohol preferring rats; Beta endorphin; Ethanol; Free choice procedure; Levetiracetam

Indexed keywords

ALCOHOL; BETA ENDORPHIN; ETIRACETAM;

ALCOHOL CONSUMPTION; ALCOHOLISM; ANIMAL EXPERIMENT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT;

ALCOHOL DRINKING; ALCOHOLISM; ANIMALS; ANTICONVULSANTS; BETA-ENDORPHIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ETHANOL; FEMALE; HUMANS; PIRACETAM; RATS; RATS, INBRED STRAINS; SELF ADMINISTRATION; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 78951477309     PISSN: 00319384     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.physbeh.2010.12.021     Document Type: Article

References (26)

1. Johannessen Landmark C. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs 2008, 22:27-47.
2. Zullino D.F., Khazaal Y., Hattenschwiler J., Borgeat F., Besson J. Anticonvulsant drugs in the treatment of substance withdrawal. Drugs Today 2004, 40:603-619.
3. Minozzi S., Amato L., Vecchi S., Davoli M. Anticonvulsants for alcohol withdrawal. Cochrane Database Syst Rev 2010, 3:CD005064.
4. Pages K.P., Ries R.K. Use of anticonvulsants in benzodiazepine withdrawal. Am J Addict 1998, 7:198-204.
5. Kosten T.R., O'Connor P.G. Menagment of drug and alcohol withdrawal. N Engl J Med 2003, 348:1786-1795.
6. LaRoche S.M. A new look at the second-generation antiepileptic drugs: a decade of experience. Neurologist 2007, 13:133-139.
7. Johnson B.A., Rosenthal N., Capece J.A., Wiegand F., Mao L., Beyers K., et al. Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial. Arch Intern Med 2008, 168:1188-1199.
8. Book S.W., Myrick H. Novel anticonvulsants in the treatment of alcoholism. Expert Opin Investig Drugs 2005, 14:371-376.
9. Lamberty Y., Gower A.J., Klitgaard H. The new antiepileptic drug levetiracetam normalizes chlordiazepoxide withdrawal-induced anxiety in mice. Eur J Pharmacol 2002, 439:101-106.
10. Gomer B., Wagner K., Frings L., Saar J., Carius A., Harle M., et al. The influence of antiepileptic drugs on cognition: a comparison of levetiracetam with topiramate. Epilepsy Behav 2007, 10:486-494.
11. Kiefer F., Horntrich M., Jahn H., Wiedemann K. Is withdrawal-induced anxiety in alcoholism based on beta-endorphin deficiency?. Psychopharmacology 2002, 162:433-437.
12. Zalewska-Kaszubska J., Czarnecka E. Deficit in beta-endorphin peptide and tendency to alcohol abuse. Peptides 2005, 26:701-705.
13. Gianoulakis C. Influence of the endogenous opioid system on high alcohol consumption and genetic predisposition to alcoholism. J Psych Neurosci 2001, 26:308-314.
14. Dai X., Thavundayil J., Gianoulakis C. Differences in the peripheral levels of β-endorphin in response to alcohol and stress as function of alcohol dependence and family history of alcoholism. Alcohol Clin Exp Res 2005, 29:1965-1975.
15. Zalewska-Kaszubska J., Gorska D., Dyr W., Czarnecka E. Effect of chronic acamprosate treatment on voluntary alcohol intake and β-endorphin plasma levels in rats selectively bred for high alcohol preference. Neurosci Lett 2008, 431:221-225.
16. Zalewska-Kaszubska J., Gorska D., Dyr W., Czarnecka E. Voluntary alcohol consumption and plasma beta-endorphin levels in alcohol-preferring rats chronically treated with naltrexone. Physiol Behav 2008, 93:1005-1010.
17. Zalewska-Kaszubska J., Gorska D., Dyr W., Czarnecka E. Effect of repeated treatment with topiramate on the beta-endorphin plasma level in rats selectively bred for high and low alcohol preference. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:525-528.
18. Sarid-Segal O., Piechniczek-Buczek J., Knapp C., Afshar M., Devine E., Sickles L., et al. The effects of levetiracetam on alcohol consumption in alcohol-dependent subjects: an open label study. Am J Drug Alcohol Abuse 2008, 34:441-447.
19. Zalewska-Kaszubska J., Gorska D., Dyr W., Czarnecka E. Lack of changes in beta-endorphin plasma levels after repeated treatment with fluoxetine: possible implications for the treatment of alcoholism - a pilot study. Pharmazie 2008, 63:308-311.
20. Krebs M., Leopold K., Richter C., Kienast T., Hinzpeter A., Heinz A., et al. Levetiracetam for the treatment of alcohol withdrawal syndrome: an open-label pilot trial. J Clin Psychopharmacol 2006, 26:347-349.
21. Mariani J.J., Levin F.R. Levetiracetam for the treatment of co-occurring alcohol dependence and anxiety: case series and review. Am J Drug Alcohol Abuse 2008, 34:683-691.
22. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 2004, 101:9861-9866.
23. Yang X.F., Weisenfeld A., Rothman S.M. Prolonged exposure to levetiracetam reveals a presynaptic effect on neurotransmission. Epilepsia 2007, 48:1861-1869.
24. Rigo J.M., Hans G., Nguyen L., Rocher V., Belachew S., Malgrange B., et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol 2002, 136:659-672.
25. Lukyanetz E.A., Shkryl V.M., Kostyuk P.G. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 2002, 43:9-18.
26. Di Chiara G. Alcohol and dopamine. Alcohol Health Res World 1997, 21:108-114.